Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD

4.48  +0.15 (+3.46%)

Fundamental Rating

3

Taking everything into account, ABSI scores 3 out of 10 in our fundamental rating. ABSI was compared to 572 industry peers in the Biotechnology industry. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability. ABSI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABSI had negative earnings in the past year.
ABSI had a negative operating cash flow in the past year.
In the past 5 years ABSI always reported negative net income.
ABSI had a negative operating cash flow in each of the past 5 years.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

ABSI has a Return On Assets (-41.52%) which is in line with its industry peers.
ABSI's Return On Equity of -48.51% is fine compared to the rest of the industry. ABSI outperforms 66.90% of its industry peers.
Industry RankSector Rank
ROA -41.52%
ROE -48.51%
ROIC N/A
ROA(3y)-35.93%
ROA(5y)-57.21%
ROE(3y)-43.06%
ROE(5y)-81.76%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABSI has been increased compared to 1 year ago.
ABSI has a better debt/assets ratio than last year.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

ABSI has an Altman-Z score of 5.13. This indicates that ABSI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ABSI (5.13) is better than 81.42% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ABSI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, ABSI perfoms like the industry average, outperforming 42.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 5.13
ROIC/WACCN/A
WACC9.43%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

ABSI has a Current Ratio of 5.63. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.63, ABSI perfoms like the industry average, outperforming 59.12% of the companies in the same industry.
ABSI has a Quick Ratio of 5.63. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Quick ratio (5.63) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.63
Quick Ratio 5.63
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.48% over the past year.
The Revenue for ABSI has decreased by -39.38% in the past year. This is quite bad
ABSI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.15% yearly.
EPS 1Y (TTM)19.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-39.38%
Revenue growth 3Y6.15%
Revenue growth 5YN/A
Sales Q2Q%128.63%

3.2 Future

Based on estimates for the next years, ABSI will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.12% on average per year.
The Revenue is expected to grow by 55.01% on average over the next years. This is a very strong growth
EPS Next Y22.66%
EPS Next 2Y14.2%
EPS Next 3Y11.31%
EPS Next 5Y9.12%
Revenue Next Year-5.53%
Revenue Next 2Y57.43%
Revenue Next 3Y73.93%
Revenue Next 5Y55.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.2%
EPS Next 3Y11.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABSCI CORP

NASDAQ:ABSI (2/11/2025, 11:44:06 AM)

4.48

+0.15 (+3.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners60.53%
Inst Owner Change-51.06%
Ins Owners7.81%
Ins Owner Change-0.31%
Market Cap514.57M
Analysts82.67
Price Target8.8 (96.43%)
Short Float %23.36%
Short Ratio4.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.87%
Min EPS beat(2)-13.12%
Max EPS beat(2)-10.61%
EPS beat(4)0
Avg EPS beat(4)-6.67%
Min EPS beat(4)-13.12%
Max EPS beat(4)-1.23%
EPS beat(8)1
Avg EPS beat(8)-12.44%
EPS beat(12)1
Avg EPS beat(12)-11.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.79%
Min Revenue beat(2)-34.7%
Max Revenue beat(2)-4.87%
Revenue beat(4)0
Avg Revenue beat(4)-41.35%
Min Revenue beat(4)-67.78%
Max Revenue beat(4)-4.87%
Revenue beat(8)1
Avg Revenue beat(8)-39.83%
Revenue beat(12)2
Avg Revenue beat(12)-34.2%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.34%
PT rev (3m)4.1%
EPS NQ rev (1m)3.93%
EPS NQ rev (3m)-15.81%
EPS NY rev (1m)0.16%
EPS NY rev (3m)-6.15%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)-12.88%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-1.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 122.31
P/FCF N/A
P/OCF N/A
P/B 2.56
P/tB 3.31
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.04
BVpS1.75
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.52%
ROE -48.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.93%
ROA(5y)-57.21%
ROE(3y)-43.06%
ROE(5y)-81.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.94%
Cap/Sales 9.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.63
Quick Ratio 5.63
Altman-Z 5.13
F-Score4
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)234.14%
Cap/Depr(5y)223.96%
Cap/Sales(3y)364.15%
Cap/Sales(5y)238.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y22.66%
EPS Next 2Y14.2%
EPS Next 3Y11.31%
EPS Next 5Y9.12%
Revenue 1Y (TTM)-39.38%
Revenue growth 3Y6.15%
Revenue growth 5YN/A
Sales Q2Q%128.63%
Revenue Next Year-5.53%
Revenue Next 2Y57.43%
Revenue Next 3Y73.93%
Revenue Next 5Y55.01%
EBIT growth 1Y-14.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.26%
EBIT Next 3Y11.57%
EBIT Next 5YN/A
FCF growth 1Y31.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.88%
OCF growth 3YN/A
OCF growth 5YN/A